+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Preventive Medicines Market - Global Forecast 2026-2032- Product Image
Preventive Medicines Market - Global Forecast 2026-2032- Product Image
Sale

Preventive Medicines Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5637024
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Preventive Medicines Market is projected to reach USD 479.91 Billion in 2026. It is expected to continue growing at a CAGR of 9.14%, reaching USD 816.10 Billion by 2032.

Preventive medicines are moving from a narrow focus on vaccination and prophylaxis to a broader evidence-based model that includes immunization, pre-exposure prophylaxis, chemoprevention, cardiometabolic risk reduction, maternal and child health interventions, and preventive therapies supported by diagnostics. The category is gaining strategic importance because chronic and infectious diseases continue to account for a large share of avoidable mortality, while health systems face rising costs from late-stage treatment and preventable hospital utilization.

The business case is strongly supported by public health data. The World Health Organization reports that immunization prevents an estimated 3.5 million to 5 million deaths each year, and the CDC notes that six in ten adults in the United States live with at least one chronic disease. These realities are increasing demand for preventive medicine strategies that lower disease incidence, improve population health outcomes, strengthen health system resilience, and reduce avoidable hospitalizations.

Transformative Shifts in the Preventive Medicines Landscape

The preventive medicines landscape is being reshaped by adult immunization, personalized risk stratification, antimicrobial resistance preparedness, and the growing use of real-world evidence. Health systems are prioritizing earlier intervention as cancer screening, cardiovascular prevention, obesity management, maternal health, and infectious disease prevention converge with pharmacy access, primary care workflows, and digital patient engagement.

A major shift is the expansion of prevention beyond pediatric programs. Aging populations, post-pandemic preparedness, and higher awareness of respiratory viruses are increasing demand for adult vaccines, long-acting prophylactic options, and prevention pathways integrated into routine care. At the same time, value-based care is pushing manufacturers and providers to demonstrate measurable reductions in disease burden, not only product utilization.

Cumulative Impact of Artificial Intelligence on Prevention

Artificial intelligence is strengthening preventive medicines by improving target discovery, clinical trial design, pharmacovigilance, disease surveillance, supply planning, and patient identification. Machine learning models can analyze claims, electronic health records, genomics, and social determinants of health to identify individuals at elevated risk and support earlier intervention, while AI-enabled surveillance can help detect outbreaks and changing disease patterns faster.

The cumulative impact is operational as well as clinical. AI can improve vaccine supply planning, reduce missed opportunities for preventive care, support personalized adherence programs, and help public health teams prioritize outreach to underserved populations. However, leaders must manage algorithmic bias, data privacy, explainability, and clinical validation because preventive decisions affect healthy or asymptomatic populations and therefore require particularly strong evidence and trust.

Key Regional Insights for Preventive Medicines

Asia-Pacific is a high-priority preventive medicines region due to large populations, expanding immunization infrastructure, and rising noncommunicable disease prevalence, with China, India, Japan, South Korea, and Australia shaping demand across vaccines, screening-linked prevention, and chronic disease risk reduction. North America remains a leading innovation and commercialization hub, supported by advanced life sciences R&D, pharmacy-based vaccination, payer data infrastructure, adult immunization policy attention, and strong use of real-world evidence in healthcare decision-making.

Europe benefits from established public health systems, centralized regulatory pathways, health technology assessment, and cross-border pharmacovigilance, while Latin America continues to expand vaccine access and primary care prevention despite uneven reimbursement and health system capacity. The Middle East is investing in preventive health as part of national transformation agendas, particularly in diabetes, cardiovascular disease, cancer screening, and infectious disease preparedness. Africa presents substantial long-term need and opportunity, driven by infectious disease burden, maternal and child health priorities, vaccine-preventable disease control, and the importance of resilient cold-chain, community delivery, and access models.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are increasingly important for preventive medicines because governments are expanding immunization coverage while addressing diabetes, hypertension, tuberculosis, dengue, and aging-related risks through primary care and public health programs. The GCC is advancing preventive health through national screening, digital health platforms, vaccination campaigns, and chronic disease programs, reflecting the region’s high cardiometabolic burden and strong public investment capacity.

The European Union provides a structured environment for preventive medicine adoption through coordinated regulation, pharmacovigilance, joint health data initiatives, and public health collaboration, although country-level reimbursement still determines speed of uptake. BRICS countries combine major population scale with manufacturing capacity and growing domestic innovation, making them central to vaccine security, local production, and cost-effective prevention. G7 markets lead in premium innovation, real-world evidence, adult immunization policy, and health economic assessment, while NATO countries increasingly view biosecurity, pandemic preparedness, antimicrobial resistance readiness, and medical supply resilience as strategic priorities for national security and public health.

Key Country Insights for Preventive Medicines

The United States leads in preventive medicine innovation through biotechnology investment, adult immunization infrastructure, pharmacy access, and payer analytics, while Canada emphasizes publicly funded vaccination, health equity, and evidence-based reimbursement. Mexico and Brazil are important Latin American markets, with Mexico strengthening prevention through public health programs and Brazil’s national immunization capabilities and public health scale supporting broad preventive initiatives across infectious and chronic disease priorities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine mature regulatory oversight with strong demand for respiratory vaccines, cancer prevention, antimicrobial stewardship, and cardiometabolic risk management, while Russia maintains a sizable domestic pharmaceutical and vaccine ecosystem. China and India are pivotal to global preventive medicine volume, manufacturing, and access, with China scaling biotechnology innovation and population health programs and India remaining a major vaccine supplier with expanding domestic prevention needs. Japan, Australia, and South Korea are advanced prevention markets supported by aging populations, strong clinical standards, national immunization programs, screening infrastructure, and high digital health readiness.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation that links preventive medicines to reductions in disease incidence, hospitalization, antimicrobial use, productivity loss, and long-term health expenditure. Market access strategies should be built early around health economic outcomes, equity of access, real-world effectiveness, safety monitoring, and alignment with national immunization or prevention guidelines.

Organizations should also invest in adult prevention pathways, pharmacy and primary care partnerships, cold-chain resilience, digital adherence tools, and AI-enabled patient identification. For global growth, leaders need differentiated strategies for high-income markets focused on value demonstration and emerging markets focused on affordability, supply reliability, local partnerships, technology transfer readiness, and public procurement alignment.

Research Methodology

This executive summary is based on a structured secondary research approach using publicly available and authoritative sources, including the World Health Organization, Centers for Disease Control and Prevention, national immunization programs, regulatory agencies, peer-reviewed literature, health technology assessment documents, and health policy publications. The analysis evaluates preventive medicine adoption across epidemiology, access, reimbursement, innovation, clinical evidence, and regional health system priorities.

The methodology applies cross-validation across multiple source categories to reduce bias and ensure factual consistency. Insights were organized by region, economic grouping, and priority country to support search relevance and strategic decision-making for stakeholders in pharmaceuticals, biotechnology, healthcare delivery, diagnostics, payers, procurement agencies, and public health.

Conclusion

Preventive medicines are becoming a core pillar of sustainable healthcare because they address disease before costly complications occur. Strong evidence for vaccination, rising chronic disease burden, population aging, antimicrobial resistance concerns, and the shift toward value-based care are creating durable demand for preventive interventions across both developed and emerging markets.

The next stage of leadership will depend on trusted evidence, equitable access, resilient supply chains, responsible use of AI, and close integration with public health priorities. Organizations that connect innovation with measurable prevention outcomes will be best positioned to improve population health and build long-term relevance in the preventive medicines market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Preventive Medicines Market, by Product Type
7.1. Introduction
7.2. Nutraceuticals
7.2.1. Herbal Extracts
7.2.2. Minerals
7.2.3. Vitamins
7.3. Prophylactic Drugs
7.3.1. Antimalarials
7.3.2. Antivirals
7.4. Vaccines
7.4.1. Inactivated Vaccines
7.4.2. Live Attenuated
7.4.3. Recombinant
8. Preventive Medicines Market, by Dosage Form
8.1. Introduction
8.2. Injectable
8.2.1. Intradermal
8.2.2. Intramuscular
8.2.3. Subcutaneous
8.3. Oral
8.3.1. Capsules
8.3.2. Syrups
8.3.3. Tablets
8.4. Topical
8.4.1. Creams
8.4.2. Gels
8.4.3. Patches
9. Preventive Medicines Market, by Disease Area
9.1. Introduction
9.2. Cancer Prevention
9.3. Cardiovascular
9.4. Infectious Disease
10. Preventive Medicines Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.2.1. Professional Services
10.2.2. Self Administration
10.3. Hospitals And Clinics
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Research Institutions
10.5. Vaccination Centers
11. Preventive Medicines Market, by Region
11.1. Asia-Pacific
11.2. North America
11.3. Latin America
11.4. Europe
11.5. Middle East
11.6. Africa
12. Preventive Medicines Market, by Group
12.1. ASEAN
12.2. GCC
12.3. European Union
12.4. BRICS
12.5. G7
12.6. NATO
13. Preventive Medicines Market, by Country
13.1. United States
13.2. Canada
13.3. Mexico
13.4. Brazil
13.5. United Kingdom
13.6. Germany
13.7. France
13.8. Russia
13.9. Italy
13.10. Spain
13.11. China
13.12. India
13.13. Japan
13.14. Australia
13.15. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. FPNV Positioning Matrix, 2025
14.3. Market Concentration Analysis, 2025
14.3.1. Concentration Ratio (CR)
14.3.2. Herfindahl Hirschman Index (HHI)
14.4. Recent Developments & Impact Analysis, 2025
14.5. Product Portfolio Analysis, 2025
14.6. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. AliveCor, Inc
15.3. Amwell Corporation
15.4. Apple Inc.
15.5. AstraZeneca PLC
15.6. Bayer AG
15.7. Becton, Dickinson and Company
15.8. CVS Health Corporation
15.9. Danaher Corporation
15.10. Dexcom, Inc.
15.11. F. Hoffmann-La Roche Ltd
15.12. Fitbit, Inc.
15.13. GlaxoSmithKline plc
15.14. Laboratory Corporation of America Holdings
15.15. Merck & Co., Inc.
15.16. Moderna, Inc.
15.17. Omron Healthcare Co., Ltd.
15.18. Pfizer Inc.
15.19. Quest Diagnostics Incorporated
15.20. Sanofi S.A.
15.21. Siemens Healthineers AG
15.22. Teladoc Health, Inc.
15.23. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL PREVENTIVE MEDICINES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL PREVENTIVE MEDICINES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
FIGURE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 17. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 19. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 21. GLOBAL PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL PREVENTIVE MEDICINES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NUTRACEUTICALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NUTRACEUTICALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NUTRACEUTICALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL HERBAL EXTRACTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MINERALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MINERALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MINERALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL VITAMINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL VITAMINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL VITAMINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PROPHYLACTIC DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL ANTIMALARIALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL ANTIMALARIALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL ANTIMALARIALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL ANTIVIRALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL ANTIVIRALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL ANTIVIRALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRADERMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRADERMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRADERMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL SYRUPS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SYRUPS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SYRUPS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CREAMS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CREAMS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CREAMS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL GELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL GELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PATCHES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PATCHES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PATCHES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CANCER PREVENTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CANCER PREVENTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL CANCER PREVENTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL INFECTIOUS DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PROFESSIONAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SELF ADMINISTRATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOSPITALS AND CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL VACCINATION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL VACCINATION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL VACCINATION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 123. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 125. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 149. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 151. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 153. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 154. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 155. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 156. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 157. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 158. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 159. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 160. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 161. EUROPE PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 166. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 175. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 176. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 177. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 178. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 179. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 180. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 181. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 182. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 183. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 184. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 185. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 187. AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 188. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 189. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 190. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 191. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 192. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 193. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 194. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 195. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 196. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 197. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 198. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 199. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 201. ASEAN PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 202. GCC PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. GCC PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 204. GCC PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 205. GCC PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 206. GCC PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 207. GCC PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 208. GCC PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 209. GCC PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 210. GCC PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 211. GCC PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 212. GCC PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. GCC PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 214. GCC PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 223. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 224. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 225. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 227. EUROPEAN UNION PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 228. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 229. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 230. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 231. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 232. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 233. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 234. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 235. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 236. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 237. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 238. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 240. BRICS PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 241. G7 PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. G7 PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 243. G7 PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 244. G7 PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 245. G7 PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 246. G7 PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 247. G7 PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 248. G7 PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 249. G7 PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 250. G7 PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 251. G7 PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 252. G7 PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 253. G7 PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 254. NATO PREVENTIVE MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 255. NATO PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 256. NATO PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 257. NATO PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 258. NATO PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 259. NATO PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 260. NATO PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 261. NATO PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 262. NATO PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 263. NATO PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 264. NATO PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 265. NATO PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 266. NATO PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 267. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 268. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 270. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 271. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 272. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 273. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 274. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 275. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 276. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 277. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 278. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 280. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 281. CANADA PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 282. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 283. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 284. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 285. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 286. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 287. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 288. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 289. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 290. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 291. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 292. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 293. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 294. MEXICO PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 296. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 297. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 298. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 299. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 300. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 301. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 302. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 303. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 304. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 305. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 306. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 307. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 308. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 309. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 310. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 311. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 312. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 313. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 314. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 315. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 316. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 317. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 318. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 319. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 320. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 321. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 322. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 323. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 324. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 325. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 326. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 327. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 328. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 329. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 330. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 332. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 333. GERMANY PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 334. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 335. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 336. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 337. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 338. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 339. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 340. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 341. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 342. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 343. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 345. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 346. FRANCE PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 348. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 349. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 350. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 351. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 352. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 353. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 354. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY TOPICAL, 2017-2032 (USD MILLION)
TABLE 355. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISEASE AREA, 2017-2032 (USD MILLION)
TABLE 356. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 357. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY HOME HEALTHCARE, 2017-2032 (USD MILLION)
TABLE 358. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS AND CLINICS, 2017-2032 (USD MILLION)
TABLE 359. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 361. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY NUTRACEUTICALS, 2017-2032 (USD MILLION)
TABLE 362. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY PROPHYLACTIC DRUGS, 2017-2032 (USD MILLION)
TABLE 363. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY VACCINES, 2017-2032 (USD MILLION)
TABLE 364. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DOSAGE FORM, 2017-2032 (USD MILLION)
TABLE 365. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 366. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY ORAL, 2017-2032 (USD MILLION)
TABLE 367. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY

Companies Mentioned

  • Abbott Laboratories
  • AliveCor, Inc
  • Amwell Corporation
  • Apple Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Becton, Dickinson and Company
  • CVS Health Corporation
  • Danaher Corporation
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd
  • Fitbit, Inc.
  • GlaxoSmithKline plc
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Omron Healthcare Co., Ltd.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Sanofi S.A.
  • Siemens Healthineers AG
  • Teladoc Health, Inc.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 479.91 Billion
Forecasted Market Value ( USD ) by 2032 $ 816.1 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned23

Related Topics

Related Reports

Antiparasitic Drugs Market - Global Forecast 2026-2032 - Product Image

Antiparasitic Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Sulphonamides Market - Global Forecast 2026-2032 - Product Image

Sulphonamides Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Sulphonamides Market - Global Strategic Business Report - Product Image

Sulphonamides Market - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Cyclooxygenase 1 Inhibitors - Global Strategic Business Report - Product Image

Cyclooxygenase 1 Inhibitors - Global Strategic Business Report

  • Report
  • 367 Pages
  • Global
From
Longevity Market Report 2026-2036 - Product Image

Longevity Market Report 2026-2036

  • Report
  • 531 Pages
  • Global
From

About the Preventive Healthcare Market

The Preventive Healthcare market is a segment of the Healthcare Services industry that focuses on the prevention of illness and injury. It includes services such as health screenings, vaccinations, and lifestyle counseling. These services are designed to help individuals maintain their health and reduce their risk of developing chronic diseases. Preventive healthcare also includes public health initiatives, such as health education campaigns and disease surveillance programs. The Preventive Healthcare market is an important part of the overall healthcare system, as it helps to reduce the burden of disease and improve the quality of life for individuals. It is also a cost-effective way to reduce healthcare costs, as preventive services can help to reduce the need for more expensive treatments. Some companies in the Preventive Healthcare market include CVS Health, UnitedHealth Group, Humana, Walgreens, and Kaiser Permanente. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.